MALO

The main purpose of the SYNERGY-OUTCOMES study is to find out whether GLP-1 medications – retatrutide and tirzepatide – can prevent progression of liver disease in people with high-risk metabolic dysfunction-associated steatotic liver disease (MASLD aka fatty liver disease).

To see if you are eligible for the study, participants will have blood tests and non-invasive liver imaging such as Fibroscan (liver ultrasound) and MRI (magnetic resonance imaging) to assess their liver health.

There are two parts to the study: the treatment period and the extension study. During the treatment period, participants will inject themselves once weekly with one of the GLP-1 drugs or a placebo (saline injection). There is a 2 to 1 chance that you will receive the study drug versus placebo. Once the treatment period has been completed, eligible participants can receive active GLP-1 medication in the extension study for an additional 2 years.

You can learn more at: https://trials.lilly.com/en-US/trial/651596